Orphan Drug

Ipsen hit by new palaver for rare disease drug palovarotene

Just as Ipsen’s $1 billion bet on rare bone disease drug palovarotene seemed to be nearing the finish line, it has fallen at the final hurdle. After a string of setbacks with the programme, Ipsen finally filed palovarotene with the FDA in May, earning a priority review. But the French drugmaker has already withdrawn it, …

Ipsen hit by new palaver for rare disease drug palovarotene Read More »

Orphan Drug Policies Around the World

How do you incentivize pharmaceutical companies and researchers to develop new drugs for rare diseases? Drug development is expensive and–by definition–rare diseases have a small market. One solution to this problem is that governments have used orphan drug policies to provide monetary incentives for innovators to research drugs for rare diseases. But which countries have …

Orphan Drug Policies Around the World Read More »